FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medical chemistry and concerns using non-peptide compounds for inhibiting the oligomerisarion of monomer peptides Aβ1-42. There are offered methods for counteracting formation of neurotoxic proteins ADDL from monomer peptides Aβ1-42, as well as methods for suppressing, regulating and/or modulating neuronal dysfunction or neurotoxicity caused by the proteins ADDL in nerve cells or nerve tissue due to suppressing formation of the proteins ADDL, involving the contact of monomer Aβ1-42 and a compound specified in a group consisting of: (Z)-N-(2-Methoxy-phenyl)-2-oxo-2-{N'-[3-oxo-3-thiophen-2-yl-1-trifluoromethyl-propylidene]-hydrazino}-acetamide, ethyl ether of (E)-2-{[1-(2-hydroxy-3-methoxy-phenyl)-methylidene-hydrazinooxalyl]-amino}-6-metyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid, ethyl ether of (E)-2-{[1-(2-hydroxynaphthalen-1-yl)-methylidene-hydrazinooxalyl]-amino}-6-metyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid, ethyl ether of (E)-2-{[1-(2-hydroxyphenyl)-methylidene-hydrazinooxalyl]-amino}-6-metyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid, 2-(5-Hydroxy-3-isobutyl-5-(triflouromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide and (E)-2-Hydroxy-N'-((1-hydroxynaphthalen-2-yl)mehtylene)banzohydrazide. There are also presented compositions containing an effective amount of the compounds stated above.
EFFECT: group of invention provides the candidate compounds for developing drug preparations for neurodegenerative disorders associated with the proteins ADDL, particularly Alzheimer's disease.
25 cl, 2 dwg, 1 tbl, 3 ex
